Main Line biotech firm completes reverse merger, raises $78.9 million
Palvella Therapeutics completed a reverse merger with Pieris Pharmaceutical of Boston to become a public traded company, with ...
After losing AstraZeneca collab, Boston biotech opts for reverse merger
After losing a major partnership last year, the Boston biotech Pieris Pharmaceutical has been searching for a path forward.